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Abstract
Background: We aimed to compare clinical and procedural characteristics of unselected
smokers and non-smokers undergoing percutaneous transluminal coronary angioplasty
(PTCA) and to assess their impact on in-hospital mortality.
Methods: One thousand consecutive patients treated interventionally were retrospectively
enrolled into a single academic centre registry.
Results: Smokers (n = 631), in comparison to non-smokers (n = 369), were younger and
less likely to be hypertensive, diabetic and female gender. History of myocardial infarction and
pre-existing heart failure were also less frequent in the group of smokers. Furthermore,
univariate analysis revealed more frequent presentation with acute coronary syndromes (ACS),
shorter overall duration of PTCA, shorter exposure to X-rays and lower volume of contrast
medium administered in smokers than in non-smokers. Conversely, non-smokers were char-
acterized by considerably higher prevalence of multivessel disease, lower completeness of
revascularization and worse final epicardial flow in primary PTCA procedures. Moreover,
non-smokers experienced higher crude in-hospital mortality than smokers in the setting of
unstable angina/non-ST-segment elevation myocardial infarction (0.0% vs. 6.0%, p = 0.0544)
and ST-segment elevation myocardial infarction (6.0% vs. 14.0%, p < 0.02). Smoking status,
when adjusted for the baseline characteristics, did not possess any predictive value in terms of
in-hospital mortality and surrogates of intervention complexity.
Conclusions: A strong trend towards decreased mortality among smokers undergoing PTCA
was observed when compared to non-smokers. However, the survival advantage might be fully
explained by the younger age of the smokers, their more favourable clinical characteristics and
less extensive coronary atherosclerosis. (Cardiol J 2007; 14: 482–492)
Key words: percutaneous transluminal coronary angioplasty, smoking,
in-hospital mortality, comorbidities
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Introduction
Coronary artery disease (CAD) imposes a signif-
icant health burden and remains a life-threatening
condition. Hence, both its prevention and treatment
are considered as priorities.
Percutaneous transluminal coronary angi-
oplasty (PTCA) in comparison with optimal phar-
macotherapy has been proven to reduce mortality
and incidences of subsequent cardiovascular events
in patients treated for myocardial infarction and
unstable angina [1, 2] and to improve quality of life
in stable angina subjects [3]. The number of percu-
taneous coronary interventions has increased dra-
matically in recent years, with more than 650,000
such procedures now performed annually in the
United States [4]. With the advent of new genera-
tions of stents, it is supposed that even more per-
cutaneous interventions will be performed as they
replace a substantial proportion of coronary bypass
procedures.
Smoking has been identified as a strong risk
factor for premature coronary atherosclerosis, athero-
thrombotic events and sudden cardiac death [5, 6].
Smoking was demonstrated to induce a hypercoag-
ulability state and to promote low-grade inflamma-
tion [7] as well as to release catecholamines that
exert pro-arrhythmogenic effects [8] and lead to an
increase of both heart rate and arterial blood pres-
sure [9]. In addition, exposure to tobacco smoke
triggers coronary artery vasoconstriction [10]
and reduces oxygen supply due to elevated carbon
monoxide levels [11]. Nevertheless, thrombolytic
trials reported lower short-term mortality rates
among smokers suffering from myocardial infarc-
tion [12–15].
The aim of the study was to compare clinical
and procedural characteristics of smokers and non-
smokers undergoing PTCA due to symptomatic
CAD and to assess their impact on in-hospital mor-
tality.
Methods
Study design and patients
One thousand consecutive patients were retro-
spectively enrolled into a single academic centre reg-
istry. All subjects were admitted to the Department
of Cardiology and Internal Medicine of the Univer-
sity Hospital in Bydgoszcz between June 2002 and
April 2003 for interventional treatment of sympto-
matic CAD. Study participants were interviewed to
obtain a detailed medical history (with a special
emphasis on comorbidities and risk factors for CAD)
and underwent a physical examination. The pa-
tients’ invasive treatment charts and their angio-
graphic recordings were analysed. According to self-
reported smoking status, participants were catego-
rized as smokers (631 patients) or non-smokers
(369 patients). The group of smokers included cur-
rent smokers (297 subjects) and former smokers
(334 subjects).
Depending on the clinical status of the patients,
PTCA was performed in 3 modes: elective — for
stable angina (SA) patients (n = 492; 49.2%); ur-
gent — for unstable angina (UA)/non-ST-segment
elevation myocardial infarction (NSTEMI) patients
(n = 164; 16.4%) and emergency — for ST-segment
elevation myocardial infarction (STEMI) patients
(n = 344; 34.4%).
The inclusion criterion was the presence of
significant (> 50% of artery diameter) stenosis in
≥ 1 clinically relevant (> 1.5 mm in diameter) cor-
onary artery supplying viable ischemic myocardial
tissue. Patients with significant stenosis of the left
main trunk were excluded from the study. All in-
tervention was carried out in compliance with
standard guidelines using a Toshiba CAS-10A an-
giography device. Each PTCA procedure was pre-
ceded by an angiographic study. Bare metal stents
were implanted at the operator’s discretion. Com-
bined final TIMI flow 2 or 3 in the dilated vessel
and residual stenosis not exceeding 20% of the
referential diameter was regarded as an effective
procedure. Complete revascularization was accom-
plished when all clinically relevant lesions (defined
above) were treated. In each case, written in-
formed consent for coronary angioplasty was re-
quired. The study protocol was approved by the
local ethics committee.
Demographic and clinical characteristics of the
study population as well as distribution of selected
angiographic and procedural features in the com-
pared groups are displayed in Tables 1 and 2, re-
spectively.
Patient management depended on the mode of
qualification for the invasive procedure. Elective
interventions were preceded by oral administration
of aspirin (75–150 mg once daily) to all patients and
additional administration of ticlopidine (250 mg
twice daily) at least 72 hours prior to PTCA. Pa-
tients qualifying for urgent/emergency procedure
were pretreated with a 300 mg loading dose of clopi-
dogrel. Independently of the mode of management
unless contraindicated, each patient was given un-
fractionated heparin intravenously (100 IU/kg) and
an intracoronary bolus of nitroglycerin (0.3 mg) di-
rectly prior to the procedure. Only iso-osmolar or
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Table 2. Angiographic and procedural characteristics of the analysed groups.
Parameters Current Former Non- p between p between p between
smokers smokers -smokers current former ever
(n = 297)  (n = 334) (n = 369)   smokers smokers smokers
and non-  and non-  and non-
-smokers  -smokers -smokers
Coronary artery disease:
single-vessel 128 (43.1%) 100 (29.9%) 94 (25.5%)
multivessel 169 (56.9%) 234 (70.1%) 275 (74.5%)
< 0.0001 NS < 0.0006
Localization of culprit lesion:
right coronary 124 (41.7%) 111 (33.2%) 136 (36.9%)
artery
left coronary artery 171 (57.6%) 219 (65.6%) 230 (62.3%)
saphenous venous 2 (0.7%) 4 (1.2%) 2 (0.5%) NS* NS* NS*
graft
left internal 0 (0%) 0 (0%) 1 (0.3%)
mammary artery
Restenosis as 5 (1.7%) 15 (4.5%) 16 (4.3%) 0.0515 NS NS
a reason for PTCA
Baseline blood flow in the culprit vessel:
TIMI 0 or 1 148 (49.8%) 100 (29.9%) 112 (30.4%)
TIMI 2 or 3 149 (50.2%) 234 (70.1%) 257 (69.6%)
< 0.0001 NS < 0.005
Baseline blood flow in the culprit vessel exclusively in STEMI patients:
TIMI 0 or 1 123 (68.3%) 53 (74.6%) 66 (71.0%)
TIMI 2 or 3 57 (31.7%) 18 (25.4%) 27 (29.0%)
NS NS NS
Table 1. Demographic and clinical characteristics of the analysed groups.
Parameters Current Former Non- p between p between p between
smokers smokers -smokers current former ever smokers
(n = 297)  (n = 334) (n = 369) smokers smokers and non-
and non- and non-  -smokers
-smokers -smokers
Age (years) 55.2 ± 10.2 59.4 ± 9.5 64.6 ± 10.8 < 0.000001 < 0.000001 < 0.000001
Male gender 236 (79.5%) 269 (80.5%) 196 (53.1%) < 0.0001 < 0.0001 < 0.0001
Indications for PTCA:
SA 80 (26.9%) 216 (64.7%) 196 (52.1%)
UA/NSTEMI 37 (12.5%) 47 (14.1%) 80 (14.1%) < 0.0001 < 0.005 < 0.0001
STEMI 180 (60.6%) 71 (21.2%) 93 (33.8%)
Cardiogenic shock 17 (5.7%) 7 (2.1%) 17 (4.6%) NS 0.067 NS
History of MI 85 (28.6%) 187 (56.0%) 182 (49.3%) < 0.0001 0.0772 0.0568
Chronic heart failure 28 (9.4%) 47 (14.1%) 70 (19.0%) < 0.0007 0.0816 < 0.03
History of stroke 13 (4.4%) 20 (6.0%) 22 (6.0%) NS NS NS
PAD 24 (8.1%) 29 (8.7%) 13 (3.5%) < 0.02 < 0.004 < 0.003
Hypertension 151 (50.8%) 199 (59.6%) 256 (69.4%) < 0.0001 < 0.007 < 0.0001
Diabetes mellitus 24 (8.1%) 61 (18.3%) 107 (29.0%) < 0.0001 < 0.001 < 0.0001
BMI [kg/m2] 26.9 ± ?3.8 27.4 ± 3.5 27.8 ± 4.0 < 0.009 NS < 0.05
Hypercholesterolemia 235 (79.1%) 286 (85.6%) 287 (77.8%) NS < 0.008 0.0635
Family history of CAD 83 (27.9%) 111 (33.2%) 84 (22.8%) NS < 0.003 < 0.007
PAD — peripheral arterial disease; PTCA — percutaneous transluminal coronary angioplasty; MI — myocardial infarction; BMI — body mass index;
CAD — coronary artery disease; SA — stable angina; UA — unstable angina; STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-
-ST-segment elevation myocardial infarction
cont.Æ
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low-osmolar non-ionic contrast media were used.
After stent implantation each patient received as-
pirin (75 mg once daily) indefinitely and ticlopidine
(250 mg twice daily) for 4 weeks. Other medications
were given when indicated by international recom-
mendations [16–18].
Table 2. cont. Angiographic and procedural characteristics of the analysed groups.
Parameters Current Former Non- p between p between p between
smokers smokers -smokers current former ever
(n = 297)  (n = 334) (n = 369)   smokers smokers smokers
and non-  and non- and non-
-smokers  -smokers -smokers
Final blood flow in the culprit vessel:
TIMI 0 or 1 19 (6.4%) 20 (6.0%) 24 (6.5%)
TIMI 2 or 3 278 (93.6%) 314 (94.0%) 345 (93.5%)
NS NS NS
Final blood flow in the culprit vessel exclusively in STEMI patients:
TIMI 0 or 1 9 (5.0%) 7 (9.9%) 11 (11.8%)
TIMI 2 or 3 171 (95.0%) 64 (90.1%) 82 (88.2%)
< 0.05 NS 0.095
Usage of abciximab 88 (29.6%) 44 (13.2%) 54 (14.6%) < 0.0001 NS < 0.02
Recanalization of 35 (11.8%) 32 (9.6%) 41 (11.1%) NS NS NS
chronic total
occlusion
Multivessel PTCA 8 (2.7%) 10 (3.0%) 11 (3.0%) NS NS NS
Applied PTCA method:
POBA 36 (12.1%) 71 (21.3%) 71 (19.2%)
stenting 261 (87.9%) 263 (78.7%) 298 (80.8%)
< 0.02 NS NS
Direct stenting 100 (33.7%) 82 (24.5%) 89 (24.1%) < 0.007 NS NS
Maximal stent or 17.3 ± 5.4 17.5 ± 5.8 17.4 ± 5.6 NS NS NS
balloon length [mm]
Maximal stent or 3.1 ± 0.5 3.0 ± 0.5 3.0 ± 0.5 < 0.002 NS < 0.05
balloon diameter [mm]
Maximal inflation 13.6 ± 3.3 13.6 ± 3.3 13.3 ± 3.4 NS NS NS
pressure [atm]
Number of used 1.0 ± 0.8 1.0 ± 0.8 1.1 ± 0.8 NS NS NS
balloons
Number of implanted 1.1 ± 0.6 0.9 ± 0.6 1.0 ± 0.7 NS NS NS
stents
Duration of PTCA 36.0 ± 20.7 39.0 ± 18.0 41.6 ± 22.3 < 0.00008 NS < 0.004
[min]
X-ray exposure time 8.9 ± 6.4 10.1 ± 6.2 10.6 ± 6.8 < 0.00002 NS < 0.003
[min]
Volume of dye 144.9 ± 80.1 150.1 ± 69.6 158.7 ± 83.4 < 0.02 NS 0.057
used [ml]
Angiographic outcome of PTCA:
effective 279 (93.9%) 310 (92.8%) 342 (93.2%)
ineffective 18 (6.1%) 24 (7.2%) 27 (6.8%)
NS NS NS
Revascularization:
complete 113 (38.0%) 84 (25.1%) 74 (20.1%)
incomplete 184 (62.0%) 250 (74.9%) 295 (79.9%)
< 0.0001 NS < 0.0002
Qualification for further treatment:
conservative 249 (83.8%) 271 (81.1%) 303 (82.1%)
PTCA 43 (14.5%) 55 (16.5%) 57 (15.4%) NS NS NS
CABG 5 (1.7%) 8 (2.4%) 9 (2.4%)
*Saphenous venous grafts and left internal mammary arteries were analysed as one group; PTCA — percutaneous transluminal coronary angioplasty;
STEMI — ST-segment elevation myocardial infarction; CABG — coronary artery bypass grafting; POBA — plain old balloon angioplasty
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Statistical analysis
Quantitative and qualitative data were respec-
tively reported as arithmetical mean ± standard
deviation and the sum and percentage of patients
within the analysed group, presenting with a par-
ticular feature. Arithmetical means and percentage
values were rounded off to one decimal place and
odd ratio values to two decimal places. Examina-
tion of normal distribution of quantitative variables
was performed using the Shapiro-Wilk test. Con-
tinuous variables showing normal distribution were
compared with the t-test for the difference between
two means of independent variables. The Mann-
-Whitney test was applied to compare variables
which did not show Gaussian distribution. Inde-
pendent prognostic factors of the short-term out-
come were determined with the logistic regression
model. Relations between the investigated varia-
bles and the likelihood of in-hospital mortality were
estimated with the use of odds ratios (OR) and their
95% confidence intervals (95% CI). A multiple re-
gression model was used to evaluate the independ-
ent impact of multiple variables on a continuous
variable. Qualitative data were analysed and com-
pared using the c2 test (applying Yeats’ correction
when indicated) or using the Fisher exact test.
A value of p < 0.05 was considered statistically sig-
nificant; 0.05 £ p < 0.1 was regarded as a trend to-
wards statistical significance, while p ≥ 0.1 was
marked as NS. All computations were carried out
with Statistica, version 7.1 (StatSoft, Tulsa, USA).
Results
Patient and procedure characteristics
Smokers, when compared to non-smokers,
were referred for PTCA at a younger age (detailed
comparisons with respect to clinical presentation:
SA 56.7 ± 9.0 years vs. 61.9 ± 9.6 years, p <
< 0.000001; UA/NSTEMI 59.2 ± 11.8 years vs. 66.0 ±
± 10.9 years, p < 0.0003; STEMI 57.7 ± 10.5 years
vs. 69.1 ± 11.3 years, p < 0.000001). An average
smoker in our cohort experienced his/her first STEMI
almost 13 years earlier than a non-smoker (57.0 ±
± 10.0 years vs. 69.7 ± 11.7 years, p < 0.000001).
However, as indicated in Table 1, smokers were
less likely to be hypertensive, obese, diabetic and
female as well as to have less frequent history of
myocardial infarction and chronic heart failure. Fur-
thermore, univariate analysis revealed more fre-
quent presentation with acute coronary syndromes
and higher frequency of both family history of CAD
and peripheral arterial disease in smokers than in
non-smokers. Despite a tendency towards more
frequent detection of hypercholesterolemia in
smokers, rates of declared prior statin therapy were
comparable in both groups. Smoking and non-smok-
ing subjects did not differ significantly in terms of
culprit lesion localization, baseline TIMI flow in the
culprit vessel corrected for the clinical presentation
or occurrence of cardiogenic shock (Table 2). PTCA
in non-smokers was associated with longer overall
duration, longer exposure to X-rays and higher vol-
ume of injected contrast medium, despite similar
distributions of multivessel PTCA, recanalization
of chronic total occlusions, stent application, direct
stenting and the number of used balloons in the
compared populations. Non-smokers were also
characterized by a higher prevalence of multives-
sel coronary disease and lower diameter of refer-
ence vessel. On the other hand, abciximab was more
frequently administered in smokers.
The angiographic efficacy of intervention meas-
ured as a proportion of patients with final TIMI
2 or 3 flow in the culprit vessel was high in both
groups, without any significant differences. How-
ever, a lower completeness of revascularization and
a tendency towards worse final epicardial flow in the
setting of STEMI were observed in non-smokers.
In-hospital mortality and
duration of hospitalisation
We noted an unadjusted in-hospital mortality
rate of 2.4% in smokers compared with 4.6% in non-
-smokers (p = 0.0532). A subgroup analysis of in-
hospital mortality with respect to the indication for
PTCA revealed elevated mortality rates among non-
smokers after interventions carried out for STEMI
and UA/NSTEMI (Fig. 1). A detailed comparison of
patients treated for STEMI demonstrated significant-
Figure 1. Comparison of in-hospital mortality rates; SA
— stable angina; UA — unstable angina; STEMI — ST-
-segment elevation myocardial infarction; NSTEMI
— non-ST-segment elevation myocardial infarction.
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ly lower in-hospital mortality in current smokers
than in non-smokers (4.4% vs. 14.0%, p < 0.006).
Mortality rates did not differ significantly between
former smokers and non-smokers (9.9% vs. 14.0%,
p = NS) as well as current smokers and former
smokers (4.4% vs. 9.9%, p = NS). Although after
exclusion of subjects presenting with cardiogenic
shock absolute mortality rates substantially de-
creased, trends towards lower in-hospital mortali-
ty in smokers persisted (Fig. 2). However, mortal-
ity rates in the setting of primary PTCA in patients
without symptoms of cardiogenic shock were com-
parable when analysed separately in current smok-
ers, former smokers and non-smokers (1.2% vs.
4.7% vs. 5.2%, p for all comparisons = NS). We
noticed a high in-hospital mortality in subjects with
STEMI complicated with cardiogenic shock, with
no difference relating to smoking status (41.7% vs.
56.2%, p = NS).
The total duration of hospitalisation was simi-
lar in smoking and non-smoking patients (5.3 ± 5.4
days vs. 5.1 ± 5.9 days, p = NS). As far as the rela-
tion between the duration of hospitalisation and
particular indication for PTCA is concerned, a trend
towards prolongation of in-hospital stay was noted
in non-smokers suffering from STEMI (SA 3.1 ±
± 5.2 days vs. 2.8 ± 3.1 days, p = NS; UA/NSTEMI
6.5 ± 6.6 days vs. 7.7 ± 8.9 days, p = NS; STEMI
8.3 ± 4.8 days vs. 7.6 ± 4.5 days, p = 0.093).
Multivariate analyses
Smoking status, when adjusted for the baseline
characteristics from Tables 1 and 2, did not possess
any predictive value in terms of in-hospital mortal-
ity (OR for non-smokers vs. smokers 1.73, 95% CI
0.61–4.91, p = NS) (Table 3).
Moreover, all considered surrogates of inter-
vention complexity (overall PTCA duration, dura-
tion of exposure to X-rays and volume of adminis-
tered contrast medium) were not influenced by
smoking when corrected for variables from Tables
1 and 2.
Discussion
Despite widespread awareness of its deleteri-
ous effect, smoking remains the single largest pre-
ventable cause of cardiovascular morbidity and pre-
mature death in developed countries [19]. Smok-
ers in our study experienced their first STEMI more
than a decade earlier when compared to non-smok-
ers. In the INTERHEART trial investigating 27,089
participants from 52 countries current smoking was
associated with an almost 3-fold greater risk of non-
fatal acute myocardial infarction compared with
never smoking. Although the odds ratio for former
smokers fell below 2 within 3 years of quitting,
Table 3. Independent predictors of in-hospital mortality in the entire investigated population.
Variable Variant OR 95% CI p
Cardiogenic shock Present vs. absent 35.74 11.39–112.20 < 0.0001
Final flow in the culprit vessel TIMI 0 or 1 vs. TIMI 2 or 3 6.09 1.77–20.99 < 0.005
STEMI vs. SA 10.43 1.72–63.43
< 0.02
STEMI vs. UA/NSTEMI vs. SA 3.23 1.31–7.96
History of diabetes mellitus True vs. false 5.00 1.70–14.73 < 0.004
Gender Male vs. female 3.68 1.13–12.01 < 0.04
History of myocardial infarction True vs. false 2.97 1.06–8.36 < 0.04
Body mass index (BMI) 1 kg/m2 increase in BMI 1.14 1.01–1.29 < 0.04
Age 1 year increase in age 1.05 1.01–1.10 < 0.03
History of statin therapy True vs. false 0.18 0.06–0.55 < 0.003
SA — stable angina; UA — unstable angina; STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-ST-segment elevation myocardial
infarction; OR — odds ratio; CI — confidence intervals
Figure 2. Comparison of in-hospital mortality rates after
exeluding patients with cardiogenic shock; SA — sta-
ble angina; UA — unstable angina; STEMI — ST-
-segment elevation myocardial infarction; NSTEMI
— non-ST-segment elevation myocardial infarction.
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a residual excess risk persisted 20 or more years
after quitting [20].
Paradoxically, thrombolytic trials consistently
revealed lower mortality rates among smokers suf-
fering from STEMI, ranging from 2.3–4.7% in cur-
rent smokers to 5.2–7.6% in former smokers and
7.0–13.8% in non-smokers [21]. These reports re-
ceive inappropriate attention in the lay press and
are often cited by smokers as another excuse for
not giving up their habit [22]. Various mechanisms
underlying the phenomenon were proposed. Post-
mortem and angiographic studies postulated throm-
bosis as the predominant cause of acute coronary
syndromes in smokers while critical residual coro-
nary stenoses were more frequently found in non-
smokers [12, 14]. Pathologic observations from vic-
tims of sudden coronary death indicated that smok-
ing cigarettes increased the risk of plaque rupture
and acute thrombosis of a lipid-rich, thin-capped
atheroma in men [23]. In contrast, in female smok-
ers plaque erosion with superimposed thrombosis
was the prevailing mechanism [24]. Furthermore,
hypercoagulable states including hyperfibrinogen-
emia, increased platelet aggregation, and more
platelet-dependent thrombin generation was attrib-
uted to the greater thrombus burden as well as its
particular susceptibility to thrombolysis in smok-
ers [25]. In support of this hypothesis, thrombolyt-
ic trials reported higher rates of TIMI grade 3 flow
restoration in the infarct-related artery in smokers
than in non-smokers [12, 13, 26, 27]. According to
latest studies, smoking stimulates the development
of collateral circulation [28, 29]. Albeit, due to lim-
ited sample sizes we can not exclude the confound-
ing effect of diabetes mellitus, more frequent in non-
smokers, that impairs recruitment of collateral ves-
sels [30, 31]. Another explanation for the smoker’s
paradox in the thrombolytic era may be fewer co-
existing high-risk features (older age, diabetes,
chronic heart failure, hypertension) in smokers with
STEMI [12, 13, 32, 33]. However, after publication
of an extensive analysis of over 500,000 STEMI
patients undergoing thrombolysis the theory sug-
gesting that baseline characteristics entirely ac-
count for unfavourable in-hospital prognosis is not
commonly believed [34]. A large international reg-
istry revealed a higher in-hospital utilization of ev-
idence-based therapies such aspirin, thrombolytics,
glycoprotein IIb/IIIa receptor inhibitors, beta-blockers
and statins in smokers when compared to non-
smokers across a broad spectrum of acute coronary
syndromes [35].
We observed a strong trend towards lower
unadjusted in-hospital mortality rates among smok-
ers with STEMI and UA/NSTEMI treated interven-
tionally when compared to non-smokers. Howev-
er, non-smokers were characterized by their older
age than smokers as well as numerous comorbidi-
ties that adversely affected prognosis. Therefore,
after correction for the baseline characteristics
smoking was no longer associated with more fa-
vourable in-hospital outcomes. The higher propor-
tion of smokers than non-smokers diagnosed with
acute coronary syndromes in our study should be
interpreted with caution. Smokers may be more
prone to develop vulnerable plaques and hence have
more episodes of acute myocardial ischemia. On the
other hand, they may be less likely to be referred
for elective procedures.
Our data represent a wide spectrum of consec-
utive patients referred to the catheterisation labo-
ratory for coronary angioplasty. In the real world
setting, we confirm observations concerning the
smoker’s paradox derived mostly from post hoc
analyses of randomised trials recruiting highly se-
lected subjects [36–38]. Many of these studies ex-
cluded subjects presenting with cardiogenic shock
[36, 37] who constitute a particularly challenging
subgroup accounting for a substantial proportion of
mortality. Similarly, elderly patients as well as sub-
jects with serious or disabling conditions such as
chronic heart failure and previous stroke have only
a slender representation in these trials. Our mate-
rial extends observations formulated on the basis
of very few studies recruiting unselected patients
to contemporary clinical practice with frequent uti-
lization of evidence-based medical therapies and
interventional devices.
Weisz et al. [37] analysing data obtained in the
randomised CADILLAC trial found the lowest mor-
tality in current smokers, intermediate in former
smokers, and highest in non-smokers at 30 days
(1.3% vs. 1.7% vs. 3.5%, respectively, p = 0.02) and
1 year (2.9% vs. 3.7% vs. 6.6%, respectively, p =
= 0.0008). In addition, rates of reinfarction were
lower in current smokers during 1-year follow-up
period, resulting in lower composite rates of major
adverse cardiac events in cigarette smokers. In-
deed, a “dose-response” curve was evident, with
the greatest protection from mortality and reinfarc-
tion in those who smoked the most. However, af-
ter a multivariate correction for differences in base-
line variables, current smoking status was no long-
er protective against late mortality in this low-risk
population with STEMI.
In a subanalysis of PAMI trial non-smokers
(n = 128) treated with primary PTCA for STEMI
had a lower frequency of in-hospital death and
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nonfatal recurrent myocardial infarction (7% vs. 18%,
p = 0.05), in-hospital ischemia (11% vs. 33%, p =
= 0.004), or the combined event (13% vs. 40%, p =
= 0.001) compared with counterparts who were given
tissue plasminogen activator [36]. Conversely, in
smokers (n = 168), the treatment strategy did not
significantly affect hospital outcomes: recurrent
ischemia (12% vs. 23%, p = 0.07), death and recur-
rent AMI (6% vs. 8%, p = 0.55), or the combined
event (15% vs. 25%, p = 0.12). Quite the opposite
to PAMI investigators, Hasdai et al. [38] found from
analysis of the GUSTO IIb study that primary PTCA
was associated with a better 30-day outcome than
tissue plasminogen activator, regardless of smok-
ing status.
Contrary to the CADILLAC trial, Kinjo and co-
workers after an analysis of 2,579 patients with
acute myocardial infarction from the OACIS study
found a markedly higher adjusted mortality in persist-
ent smokers than in non-smokers (hazard ratio 2.27;
95% CI 1.17–4.44) during an average follow-up of 885
days [39]. Additionally, smoking cessation was
identified as an independent predictor of reduced
mortality (hazard ratio 0.39; 95% CI 0.20–0.77).
Study participants were predominantly (> 80%)
treated with primary PTCA.
Gąsior et al. [40] evaluating a large cohort of
consecutive patients (n = 1,176) from the Silesian
Centre for Heart Disease treated mainly with pro-
visional stenting for STEMI concluded that differ-
ences in the baseline characteristics (younger age
of smokers and less female, diabetic or hyperten-
sive subjects in the smoking group) have a crucial
impact on better in-hospital outcome in smokers.
What is more, investigators noted a higher inci-
dence of cardiogenic shock among non-smokers
(16% vs. 8%, p < 0.001). After an adjustment for
the clinical characteristics, smokers and non-smok-
ers did not differ in terms of in-hospital mortality.
However, in our material, in comparison to the data
from Zabrze, stents were implanted much more fre-
quently (82.2% vs. 59.2%) and a remarkably high
proportion of patients received abciximab (18.6% vs.
4.7%), which reflects contemporary standards in in-
terventional cardiology. Direct comparison between
studies may also be affected by a substantial number
of rescue PTCA procedures performed after failed
thrombolysis (n = 433) in the cited study. Due to
full coverage of our region by interventional centres
providing primary PTCA in STEMI, such patients are
very infrequent in our institution. All cases of inter-
ventions in STEMI in our study were primary PTCA.
Due to a greater thrombotic component, smok-
ers presenting with acute coronary syndromes may
derive particular benefit from a potent antiplatelet
therapy. Subanalysis of REPLACE-2 trial indicat-
ed that smokers (n = 1,558) undergoing percuta-
neous coronary interventions on adjunctive treat-
ment with bivalirudin had an absolute 3.2% increase
in the composite end point of death and myocardial
infarction at 48 hours compared with smokers who
were treated with heparin and abciximab (7.7% vs.
4.5%, p = 0.008) [41]. This effect was absent in
4,305 non-smokers as well as in the general popu-
lation. Based on such suggestions and considering
age-related risk of bleeding, operators from our
centre were more likely to administer abciximab to
smokers.
Conflicting data regarding the role of smoking
on the outcomes of the elective PTCA procedures
have been published. Hasdai et al. [42] reported that
current smokers undergoing elective PTCA had
fewer adverse events than non-smokers and former
smokers and less often required repeat revascular-
izations during a mean of 4.5 years. What is of great
importance is that persistent smokers, after correc-
tion for the baseline characteristics, were at high-
er risk for both death and Q-wave myocardial inf-
arction. Unfortunately, due to limited follow-up, we
did not evaluate this problem in our material. Oth-
er studies found similar [43] or increased [44] rates
of restenosis after elective PTCA in smokers. Fi-
nally, Cohen et al. [45] after a retrospective analy-
sis of 8,671 patients from 9 trials concluded that
smoking was associated with lower rates of target
lesion revascularizations with no impact on angio-
graphic restenosis. Several possible explanations
for lower repeat (target and non-target) revascular-
ization rates were proposed [42]. Firstly, physicians
may be reluctant to perform subsequent PTCA pro-
cedures in patients who continue to smoke. Second-
ly, a slightly higher proportion of smokers in com-
parison to non-smokers in whom complete revas-
cularizations was achieved may necessitate further
interventions in the latter group. And thirdly, more
frequent risk factors for CAD (diabetes mellitus,
hypertension) in non-smokers accelerate the pro-
gression of coronary atherosclerosis.
Major study limitations include its retrospec-
tive character, the use of registry data and single
centre experience. Due to the relatively infrequent
incidence of end point events the study may be
underpowered to differentiate between current and
former smokers. Therefore, in numerous analyses
we compared ever smokers with non-smokers. In
addition, the patients’ reporting of their smoking
status may not have been accurate in all cases. The
study results apply only to patients who reached the
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hospital. A considerable numbers of patients with
acute coronary syndromes die before admission.
The issue of whether or not smoking status influ-
ences prehospital mortality rates is still a subject
of discussion. In the only study known to us, which
addresses this problem, smokers (n = 2,166) when
compared to non-smokers (n = 1,088) had a higher
risk of dying before hospital admission but the dif-
ference was not significant (OR 1.09; 95% CI 0.93–
1.27) [46]. However, unexpectedly high prehospi-
tal mortality rates (38.4% in smokers vs. 37.6% in
non-smokers) question the credibility of these find-
ings. We also investigated a heterogeneous popu-
lation in terms of CAD manifestation. Even though
we adjusted for the clinical presentation in a multi-
variable analysis, deaths occurred mostly in STE-
MI patients. Additionally, it would be valuable to
extend follow-up beyond the hospital discharge.
Conclusions
To conclude, a strong trend towards decreased
mortality among smokers undergoing PTCA was
observed when compared to non-smokers. The sur-
vival advantage is not a consequence of smoking
status per se making the commonly used term
“smoker’s paradox” misleading. This difference
may be fully explained by the younger age of smok-
ers, their more favourable clinical characteristics
and less extensive coronary atherosclerosis. In fact,
smoking contributes to the occurrence of acute
coronary syndromes at a younger age and no con-
vincing evidence concerning a protective role of
smoking in the interventional setting exists. Final-
ly, bearing in mind the results of primary and sec-
ondary prevention trials clearly indicating benefi-
cial effects of a non-smoking lifestyle and smoking
cessation, any form of smoking should be strongly
discouraged.
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